icon-    folder.gif   Conference Reports for NATAP  
 
  20th Conference on Retroviruses and
Opportunistic Infections
Atlanta, GA March 3 - 6, 2013
Back grey_arrow_rt.gif
 
 
 
COSMOS Study: SVR4 results of a once daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 null responders
 
 
  Reported by Jules Levin
CROI 2013 March 3-6
 
E Lawitz,1 R Ghalib,2 M Rodriguez-Torres,3 Z Younossi,4 A Corregidor,5 I Jacobson,6 K Callewaert,7 W Symonds,8 G Picchio,9 K Lindsay9 1The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA. 2The Liver Institute, Dallas, TX, USA. 3Fundacion de Investigacion, San Juan, Puerto Rico, USA. 4Inova Fairfax Hospital, Falls Church, VA, USA. 5Borland-Groover Clinic, Jacksonville, FL, USA. 6Weill Cornell Medical College, New York, NY, USA.7Janssen Research and Development, Beerse, Belgium.8Gilead Sciences, Inc., Foster City, CA, USA.9Janssen Research and Development LLC, Titusville, NJ, USA

CROI1.gif

CROI2.gif

CROI3.gif

CROI4.gif

CROI5.gif

CROI6.gif

CROI7.gif

CROI8.gif